Kaempferol / BioEnh Cancer Research Results

KAE, Kaempferol: Click to Expand ⟱
Features:

Kaempferol — a naturally occurring dietary flavonol polyphenol (3,4′,5,7-tetrahydroxyflavone) found in vegetables, fruits, tea, legumes, and medicinal plants, where it commonly occurs as glycosides rather than free aglycone. It is classified as a bioactive dietary flavonoid/flavonol and experimental natural-product therapeutic; common abbreviations include KMP, KPF, KF, and KAE. Major food sources include kale and other leafy vegetables, tea, broccoli, beans, onions, capers, and some fruits. Kaempferol is a multi-target compound with substantial preclinical anticancer and neuroprotective evidence, but it is not an approved anticancer or Alzheimer’s disease drug.

Primary mechanisms (ranked):

  1. PI3K/AKT/mTOR inhibition → suppression of proliferation and survival signaling, with induction of apoptosis and autophagy.
  2. Mitochondrial and death-receptor apoptosis → ↑ Bax/Bad/Bik, ↓ Bcl-2/Bcl-xL, ↑ mitochondrial permeability and cytochrome-c release, and activation of caspase-8/9/3 pathways.
  3. Cell-cycle suppression → G0/G1 or G2/M arrest depending on tumor model, with altered cyclins/CDKs and frequent participation of p53 signaling.
  4. MAPK and STAT signaling modulation → generally ↓ proliferative ERK/STAT3 signaling, while JNK/p38 effects are strongly model- and dose-dependent.
  5. NF-κB and inflammatory signaling suppression → ↓ pro-survival and inflammatory transcription, including context-dependent reductions in COX-2 and inflammatory mediators.
  6. ROS/redox modulation → frequently ↑ oxidative/mitochondrial stress in cancer cells at cytotoxic concentrations, while lower exposures in normal tissues commonly produce antioxidant and NRF2-dependent cytoprotection.
  7. Migration, EMT, invasion and angiogenesis inhibition → ↓ EGFR/Src/FAK signaling, MMP activity, HIF-1α/VEGF signaling and other metastatic programs in selected models.
  8. Metabolic suppression → inhibition of glycolysis, including PKM2-linked glycolytic metabolism in some tumor models, which can contribute to reversal of chemotherapy resistance.
  9. Ferroptosis modulation → emerging evidence indicates that kaempferol can promote ferroptotic tumor-cell death in selected cancers, while conversely suppressing pathological ferroptosis in non-cancer tissues; direction is therefore highly context-dependent.
  10. Epigenetic modulation → direct broad HDAC inhibition has been demonstrated experimentally at micromolar concentrations and may contribute to altered transcription and growth suppression.
  11. Therapy sensitization → increased responsiveness to radiation, cisplatin, TRAIL and other anticancer treatments has been demonstrated preclinically through PI3K/AKT, mitochondrial apoptosis, metabolic and drug-resistance mechanisms.

Bioavailability / PK relevance: Oral kaempferol is absorbed but undergoes extensive intestinal and hepatic conjugation, particularly glucuronidation and sulfation, so circulating material is predominantly metabolites rather than free aglycone. In a human study using 9 mg dietary kaempferol, mean plasma Cmax was approximately 0.1 µM at about 5.8 hours, with kaempferol-3-glucuronide the major circulating form. Food matrix, glycoside structure, microbiota and formulation substantially influence exposure. Nanoformulations, lipid carriers and related delivery approaches are being investigated to improve systemic exposure but remain experimental for oncology.
-research options to improve bioavailability include: take with oil (not water soluble), add Lecithin. Examples: extra virgin olive oil, nuts, egg yolk
-consuming kaempferol from kale, broccoli, onions or similar foods, most of it is present as glycosides, so mostly dependent on gut microbiota (not oil, etc)

In-vitro vs systemic exposure relevance: Most direct anticancer studies use approximately 10–100 µM kaempferol; reported IC50 values are often around 20–60 µM depending on tumor type. These concentrations generally exceed the sub-µM systemic concentrations observed after ordinary dietary exposure. Consequently, many direct cytotoxic, HDAC-inhibitory, ROS-generating and ferroptotic effects should not be assumed to occur systemically after normal dietary intake. Local gastrointestinal exposure and specialized formulations may provide different exposure conditions.
-Human dietary exposure generally produces circulating kaempferol concentrations in the nanomolar to low-submicromolar range; plasma Cmax of approximately 0.1 µM has been reported after a 9-mg dietary dose. Therefore, in-vitro exposures of 10–20 µM are roughly two orders of magnitude above concentrations demonstrated after ordinary dietary intake.

Clinical evidence status: Preclinical. Anticancer evidence consists predominantly of cell-culture and animal studies, including xenograft studies and preclinical radiosensitization/chemosensitization. There is no established therapeutic oncology indication and no convincing cancer-treatment RCT evidence for kaempferol itself. Human evidence includes epidemiologic dietary associations, pharmacokinetic studies and a small randomized safety study in healthy adults; 50 mg/day kaempferol aglycone for four weeks was well tolerated in that study. Clinical efficacy for cancer remains unproven.


Kaempferol Mechanistic Effects

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PI3K AKT mTOR ↓ PI3K; ↓ AKT; ↓ mTOR ↔ / context-dependent R–G ↓ survival and proliferation; ↑ apoptosis and autophagy One of the most reproducible anticancer axes; direct PI3K inhibition has been demonstrated experimentally.
2 Mitochondrial and death receptor apoptosis ↑ Bax/Bad/Bik; ↓ Bcl-2/Bcl-xL; ↑ Cyt-c; ↑ caspase-8/9/3 ↔ at lower exposure R–G ↑ programmed cell death Both intrinsic mitochondrial and extrinsic death-receptor pathways can participate.
3 Cell cycle and p53 ↑ p53 (model-dependent); ↑ G0/G1 or G2/M arrest G ↓ proliferation Exact checkpoint depends strongly on cancer type and exposure.
4 MAPK and STAT signaling ↓ ERK; ↓ STAT3; JNK/p38 ↔ (context-dependent) ↔ / protective MAPK modulation R–G ↓ proliferative signaling; ↑ apoptosis JNK and p38 direction is not uniform across models and should not be assigned a universal direction.
5 NF-κB inflammatory survival signaling ↓ NF-κB; ↓ p65; ↓ inflammatory and anti-apoptotic transcription ↓ pathological inflammation R–G Anti-inflammatory and anti-survival activity Potentially relevant to both tumor cells and the tumor microenvironment.
6 Mitochondrial ROS and NRF2 redox response ↑ ROS (dose-dependent); NRF2 ↔ (context-dependent) ↓ ROS; ↑ NRF2 (context-dependent) P–G Tumor oxidative stress versus normal-cell cytoprotection Biphasic redox behavior is important: pro-oxidant anticancer effects generally require substantially higher exposure than dietary systemic exposure.
7 EGFR EMT migration and angiogenesis ↓ EGFR/Src/ERK/AKT; ↓ FAK; ↓ MMPs; ↓ migration; ↓ VEGF G ↓ invasion, metastasis and angiogenesis Evidence is predominantly preclinical and varies among tumor types.
8 Glycolytic metabolism ↓ PKM2; ↓ glycolysis; ↓ lactate production (model-dependent) R–G ↓ tumor bioenergetics and drug resistance Particularly relevant to reported reversal of 5-FU resistance; not yet established as a universal kaempferol mechanism.
9 Ferroptosis ↑ ferroptosis (model-dependent) ↓ pathological ferroptosis (context-dependent) R–G Redox-dependent cell death modulation Emerging cancer evidence includes CA9-associated ferroptosis in oral squamous cell carcinoma; direction reverses in some neuroprotective models.
10 HDAC epigenetic regulation ↓ HDAC activity; ↑ histone acetylation ↔; toxicity at high concentration G Epigenetic growth suppression Pan-HDAC inhibition has been demonstrated in vitro; translational relevance is constrained by the micromolar exposure required.
11 Radio and chemosensitization ↑ radiation response; ↑ cisplatin/TRAIL response; ↓ resistance mechanisms ↔ / relative sparing in some models G Adjunct anticancer potential Demonstrated in cell and animal experiments but not established clinically.
12 Clinical Translation Constraint Required cytotoxic concentrations commonly exceed systemic dietary exposure Dietary and short-term supplemental exposures appear considerably better tolerated G PK and clinical-evidence limitation Rapid conjugation, low free-aglycone exposure, heterogeneous mechanisms and absence of therapeutic oncology trials remain major barriers.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Alzheimer’s disease: Kaempferol has substantial preclinical neuroprotective evidence in cellular and animal models of Alzheimer’s disease and sporadic dementia, but no established human therapeutic efficacy. Reported mechanisms include ↓ oxidative stress and neuroinflammation, ↓ Aβ-associated toxicity and deposition, ↓ neuronal apoptosis, modulation of AChE, improvement of synaptic/neurotrophic signaling, and suppression of pathological neuronal ferroptosis. Recent evidence implicates NRF2/HO-1/GPX4-associated antioxidant and ferroptosis-control pathways. Cognitive and memory improvements have been reported in several rodent models; these findings have not yet been validated in clinical AD trials.

Kaempferol in Alzheimer’s Disease

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Oxidative stress and NRF2 defense ↓ ROS/lipid oxidation; ↑ NRF2/HO-1 antioxidant signaling Neuronal protection One of the most consistently reported mechanisms across preclinical AD models.
2 Aβ pathology ↓ Aβ toxicity/deposition ↓ amyloid-associated neuronal injury Demonstrated in cellular and animal models; clinical relevance remains unknown.
3 Neuroinflammation ↓ inflammatory signaling ↓ neuronal inflammatory stress Likely overlaps with NF-κB and oxidative-stress modulation.
4 Neuronal ferroptosis ↓ Fe²⁺; ↓ lipid ROS; ↑ GPX4/SLC7A11/AKR1C3-associated defense ↓ ferroptotic neuronal death Emerging evidence; contrasts with pro-ferroptotic effects reported in certain cancer models.
5 Tau pathology ↓ phosphorylated Tau (model-dependent) ↓ neurodegenerative pathology Recent animal evidence; replication and human validation are required.
6 Acetylcholinesterase ↓ AChE (preclinical) Potential ↑ cholinergic signaling Evidence is substantially weaker than for approved AChE inhibitors and should not imply comparable clinical efficacy.
7 Cognition and memory ↑ learning; ↑ memory performance Functional neuroprotection Observed in several rodent models; no established human AD efficacy.


BioEnh, bioenhancer: Click to Expand ⟱
Source:
Type:
A bioenhancer is an agent capable of enhancing bioavailability and efficacy of a drug with which it is co-administered

Query Database for BioEnhancers but the bioenhancers mainly show up under the target notes

Bioenhancers
- piperine and quercetin are considered bio-enhancers
- genistein
Piperine act by suppressing P-gp and cytochrome P450 enzymes, which counteract the metabolism of rifampicin via these proteins, thus enhancing the oral bioavailability of rifampicin. It also decreases the intestinal production of glucuronic acid, thus allowing more substances to enter the body in active form. It was found to increase the bioavailability of various drugs from 30% to 200%.[25]
Table 1: Published research on bioenhancer effect of piperine with various medicines
Drug Studied in Reference
Antimicrobial agents
Rifampicin In vitro Balakrishnan et al, 2001[11]
Isoniazid Rabbits Karan et al, 1998 [12]
Pefl oxacin Mountain Gaddi goats Madhukar et al, 2008[13]
Tetracycline Rats Atal et al, 1980[14]
Sulfadiazine Rats and dogs Atal et al, 1980[14]
Oxytetracycline Poultry birds Singh et al, 2005[15]
Ampicillin Rabbits Janakiraman and Manavalan, 2008[16]
Norfl oxacin Rabbits Janakiraman and Manavalan, 2008 [16]
Nevirapine Adult males Kasibhatta et al, 2007 [17]
Metronidazole In vitro Singh et al, 2010[18]
Analgesics
Diclofenac sodium Albino mice Pooja et al, 2007[19]
Pentazocine Albino mice Pooja et al, 2007[19]
Nimesulide Mice Gupta et al, 1998[20]
Antiepileptics
Carbamazepine In vitro Pattanaik et al, 2009 [21]
Phenytoin Human volunteers Bano et al, 1987[22]
Pentobarbitone Rats Majumdar et al, 1990[23]
Other drugs
Propranolol In vitro Bano et al, 1991 [24]
Theophylline In vitro Bano et al, 1991 [24]
Nutrients In vitro Pooja et al, 2007 [19
***Borneol
-Borneol is thought to temporarily open tight junctions between endothelial cells, enhancing drug penetration. It may also downregulate efflux transporters such as P-glycoprotein (P-gp), allowing higher intracellular concentrations of co-administered drugs.

-presence of urea (as a carrier) increased the aqueous solubility of capsaicin by 3.6-fold compared to pure capsaicin

Quercetin is found in citrus fruits and is a dual inhibitor of cytochrome P 3A4 (CYP3A4) and P-gp.
Table 2: Effect of quercetin pretreatment/co-treatment on pharmacokinetic parameters of different drugs
Drugs combined Increase in pharmacokinetic parametera
Cmax AUC ABA
Verapamil Two fold Two fold SH
Diltiazem SH SH Not known
Paclitaxel SH SH T wo fold
Digoxin 413% 170% Not known
Tamoxifen SH SH 59%
Compared to drug in question alone. Cmax, peak plasma concentration; AUC, area under the curve; ABA, absolute bioavailability; SH, significantly higher.

Another flavonoid, genistein belongs to the isoflavone class of flavonoids. It is a well-known phytoestrogen. The presence of genistein (10 mg/kg) caused an increase in AUC (54.7%) and a decrease in the total plasma clearance (35.2%) after oral administration of paclitaxel at a dose of 30 mg/kg in rats.[37]
Naringin is the major flavonoid glycoside found in grapefruit and makes grapefruit juice taste bitter. Oral naringin (3.3 and 10 mg/kg) was pretreated 30 min before and after intravenous administration of paclitaxel (3 mg/kg), the AUC was significantly improved (40.8% and 49.1% for naringin doses of 3.3 and 10 mg/kg, respectively).[38

Carum carvi/Cuminum cyminum ( Jeera)
Carum carvi seeds are a prized culinary herb. Extracts of its parts increased significantly (25%–300%), the bioavailability of a number of classes of drugs, such as antibiotics, antifungals, antivirals, anticancer, cardiovascular, anti-inflammatory/ antiarthritic, anti-TB, antileprosy, antihistaminic/respiratory disorders, corticosteroids, immunosuppressants, and antiulcers. Such extracts either in the presence or absence of piperine have been found to be highly selective in their bioavailability/bioefficacy-enhancing action.[40]
Capmul
One of the widely used bioenhancers is Capmul MCM C10, a glyceryl monocaprate, produced from edible fats and oils and is commonly used in lip products. In a study in rats, antibiotic ceftriaxone when given concomitantly with capmul, increased the bioavailability of ceftriaxone by 80%.[41]
Nitrile glycoside
Nitrite glycoside is a bioenhancer for drugs and nutrients. Novel bioactive nitrile glycosides, niaziridin and niazirin is obtained from the leaves, pods, and bark of Moringa oleifera. [42] An immunoenhancing polysaccharide and niaziminin, having structural requirement to inhibit tumor promoter-induced Epstein–Barr virus activation have been reported from the leaves of Moringa.[43,44] It enhances the bioactivity of commonly used antibiotics, such as rifampicin, tetracycline, and ampicillin, and also facilitate the absorption of drugs, vitamins, and nutrients through the gastrointestinal membrane, thus increasing their bioavailability. [41] Niazirin is another bioactive nitrile glycoside belonging to M. oleifera. [45,46] Process of isolation of nitrite glycoside from M. oleifera has been patented (US 6858588) by Khanuja et al in 2004–2005. [42

Mechanism of Action Of Bioenhancers
Bioavailability-enhancing activity of natural compounds from the medicinal plants may be attributed to various mechanisms, such as P-gp inhibition activity by flavone, quercetin, and genistein; [51] inhibition of efflux transporters, such as P-gp and breast cancer resistance protein (BCRP),[52,53] by naringin and sinomenine thus preventing drug resistance; DNA receptor binding, modulation of cell signaling transduction, and inhibition of drug efflux pumps[54-56] ; by stimulating leucine amino peptidase and glycyl–glycine dipeptidase activity, thus modulating the cell membrane dynamics related to passive transport mechanism as seen with piperine [57] ; nonspecific mechanisms, such as increased blood supply to the gastrointestinal tract, decreased hydrochloric acid secretion, preventing breakdown of some drugs[6] ; and inhibition of metabolic enzymes participating in the biotransformation of drugs, thus preventing inactivation and elimination of drugs and thereby, increasing their bioavailability. [57-5]


Scientific Papers found: Click to Expand⟱
2642- Flav,  QC,  Api,  KAE,  MCT  In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type
- in-vitro, Nor, NA - in-vivo, Nor, NA
*BioAv↑, *eff↝, BioEnh↑,
8080- KAE,    Hepatoprotective Effect of Kaempferol—A Review
- Review, Nor, NA
*hepatoP↑, *SIRT1↑, *AMPK↑, *TLR4↓, *NF-kB↓, *GutMicro↑, *Dose↝, *BioAv↓, *BioAv↑, *CYP2E1↓, *lipidLev↓, *COX2/PTGS2↓, *IL1β↓, *TNF-α↓, *IL6↓, *NO↓, *PGE2↓, *iNOS↓, *SOD↑, *MDA↓, *ROS↓, *AST↓, *ALAT↓, *GSH↑, *SOD↑, *Cyt‑c↓, *BAX↓, *Casp3↓, *Casp8↓, *Casp9↓, *COL1↓, *p‑SMAD2↓, *p‑SMAD3↑, *α-SMA↓, *TGF-β↓, *P450↝, *P-gp/ABCB1↓, *BioEnh↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Drug Metabolism & Resistance(tgid=21)

BioEnh↑, 1,  
Total Targets: 1

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1)

CYP2E1↓, 1,   GSH↑, 1,   MDA↓, 1,   ROS↓, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4)

ALAT↓, 1,   AMPK↑, 1,   lipidLev↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5)

BAX↓, 1,   Casp3↓, 1,   Casp8↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   iNOS↓, 1,  

Migration(tgid=13)

COL1↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↑, 1,   TGF-β↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14)

NO↓, 1,  

Barriers & Transport(tgid=15)

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2/PTGS2↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21)

BioAv↓, 1,   BioAv↑, 2,   BioEnh↑, 1,   Dose↝, 1,   eff↝, 1,   P450↝, 1,  

Clinical Biomarkers(tgid=22)

ALAT↓, 1,   AST↓, 1,   GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23)

hepatoP↑, 1,  
Total Targets: 40

Scientific Paper Hit Count for: BioEnh, bioenhancer
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:316  Target#:1310  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page